Catherine Derenne

ClientEarth, ClientEarth (Brussels)

Catherine Derenne has been working for ClientEarth since 2021 as state aid and competition legal expert. Prior to that, Catherine Derenne was senior associate at DLA Piper in Brussels. She has vast experience in competition law including merger control, cartels and state aid.

Linked author

ClientEarth (Brussels)


2003 Bulletin

Bertold Bär-Bouyssière, Catherine Derenne Pharma and Mergers: An overview of EU and national case law


Merger control in the pharmaceutical sector follows the normal pattern of merger analysis, taking account of sectoral specificities. Mergers (used here as a shortcut for all transactions subject to merger control) can involve different types of actors, e.g. manufacturers of branded drugs (’innovators’ or ’originators’), manufacturers of generic drugs, manufacturers of biosimilars, non-manufacturing inventors, universities or start-ups, different categories of wholesalers and distributors, retailers (pharmacies), hospitals, even global investment banks, and the drugs in question can be intended for human or veterinary use. There are also mergers involving manufacturers or distributors of medical equipment, other medical products, or chemicals for use in medicinal products.


Send a message